PD-L1 TPS is simple in theory—but far more complex in practice. When eligibility for life-changing immunotherapy hinges on a 1% or 50% score, even a 5% margin of error can shift a patient’s path entirely.
This webinar takes you inside the real-world diagnostic pressure points of PD-L1 TPS testing in NSCLC. With insights drawn from clinical research, pathology practice, and oncology decision-making, we examine the human limits of PD-L1 scoring and how AI can sharpen clinical decisions.
What you’ll learn:
- The 1% that changes everything
Understand how small differences in PD-L1 Tumor Proportion Score (TPS) drastically influence therapy eligibility—and why that’s a clinical pain point. - Cut-offs, callouts, and clinical consequences
Explore why the 1% and 50% cut-offs carry outsized impact, and how subtle inconsistencies in interpretation can create major therapeutic divergence. - The human factor: why pathologists disagree
Dive into the technical, visual, and psychological reasons manual scoring is prone to variability—especially in borderline cases. - Under-called. Over-called. Mis-called.
See how PD-L1 is commonly misestimated in either direction, and how this leads to patient under-treatment or over-treatment. - AI to the assist: can algorithms outscore the experts?
Unpack the evidence on how AI is being trained to assist PD-L1 scoring—offering reproducibility, speed, and support in tough calls. - Bridging the diagnostic divide
Hear how pathologists and oncologists view PD-L1 differently—and how AI and digital tools may help unify decision-making.
Who should watch?
- Pathologists involved in biomarker testing
- Oncologists relying on PD-L1 scores for treatment planning
- Anyone involved in lung cancer diagnostics or therapeutic decision-making
